Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treatment
- DOI
- 10.3389/fphar.2021.625084
- Published
- 2021-03-19
- Container
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.3389/fphar.2021.625084,
title = {Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treatment},
author = {Shihui Bao and Hailun Zheng and Jinyao Ye and Huirong Huang and Bin Zhou and Qing Yao and Guangyong Lin and Hailin Zhang and Longfa Kou and Ruijie Chen},
year = {2021},
journal = {Frontiers in Pharmacology},
doi = {10.3389/fphar.2021.625084},
url = {https://doi.org/10.3389/fphar.2021.625084}
}RIS
TY - JOUR TI - Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treatment AU - Shihui Bao AU - Hailun Zheng AU - Jinyao Ye AU - Huirong Huang AU - Bin Zhou AU - Qing Yao AU - Guangyong Lin AU - Hailin Zhang AU - Longfa Kou AU - Ruijie Chen PY - 2021 JO - Frontiers in Pharmacology DO - 10.3389/fphar.2021.625084 UR - https://doi.org/10.3389/fphar.2021.625084 ER -
APA
Bao, S., Zheng, H., Ye, J., Huang, H., Zhou, B., Yao, Q., Lin, G., Zhang, H., Kou, L., & Chen, R. (2021). Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treatment. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2021.625084
Source records
- crossref · retrieved 2026-09-26T10:55:35.280Z